PTEN-opathies: from biological insights to evidence-based precision medicine
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The tumor suppressor phosphatase and tensin homolog (PTEN) classically counteracts the PI3K/AKT/mTOR signaling cascade. Germline pathogenic PTEN mutations cause PTEN hamartoma tumor syndrome (PHTS), featuring various benign and malignant tumors, as well as neurodevelopmental disorders such as autism spectrum disorder. Germline and somatic mosaic mutations in genes encoding components of the PI3K/AKT/mTOR pathway downstream of PTEN predispose to syndromes with partially overlapping clinical features, termed the "PTEN-opathies." Experimental models of PTEN pathway disruption uncover the molecular and cellular processes influencing clinical phenotypic manifestations. Such insights not only teach us about biological mechanisms in states of health and disease, but also enable more accurate gene-informed cancer risk assessment, medical management, and targeted therapeutics. Hence, the PTEN-opathies serve as a prototype for bedside to bench, and back to the bedside, practice of evidence-based precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · cited 1×
“Notably, AKT represents only one of many PIP3-binding proteins regulated by the PI3K/PTEN axis (13, 14).”
BackgroundLi, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083 · cited 2×
“TSC1/2 and STK11/LKB1, the susceptibility genes for TSC and PJS, respectively, are not only upstream of mTOR (9, 134) but are also downstream of PTEN signaling (135).”
BackgroundNegative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539 · cited 2×
“Loss of PTEN in the sporadic context has been associated with resistance to anti–PD-1 therapy in melanoma (121), a CS component cancer, and more recently in a case study of metastatic uterine leiomyosarcoma (162).”
BackgroundOff-target Effects in CRISPR/Cas9-mediated Genome Engineering
Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S., & Yang, S.-H. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.37 · Cited by 1,273 · cited 1×
“While gene editing poses many challenges, including off-target effects and activation of adaptive immune responses (152, 153), recent advances show promise in mitigating these outcomes (154–156).”
BackgroundThe TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237 · cited 1×
“TSC1/2 and STK11/LKB1, the susceptibility genes for TSC and PJS, respectively, are not only upstream of mTOR (9, 134) but are also downstream of PTEN signaling (135).”
BackgroundInhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN
Tamura, M., Gu, J., Matsumoto, K., Aota, S.-I., Parsons, R., & Yamada, K. M. (1998) · Science · doi:10.1126/science.280.5369.1614 · Cited by 1,215
Cited by
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
“PTEN-opathies: molecular targeted therapy The changes of PI3K/AKT/mTOR signaling pathway in PTEN mutant cancer patiens indicated that PI3K, AKT or mTOR are target for molecular therapy.(417) PTEN hamartoma tumor syndrome (PHTS) is caused by pathogenic PTEN mutation in germline.”
BackgroundImmune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Papa, A., & Pandolfi, P. P. (2019) · Biomolecules · doi:10.3390/biom9040153 · Cited by 303
Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis
Linton, M. F., Moslehi, J. J., & Babaev, V. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112703 · Cited by 285
The Clinical Spectrum of PTEN Mutations
Yehia, L., Keel, E., & Eng, C. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-052218-125823 · Cited by 253
Self-citationChida, K., Kawazoe, A., Kawazu, M., Suzuki, T., Nakamura, Y., Nakatsura, T., Kuwata, T., Ueno, T., Kuboki, Y., Kotani, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0401 · Cited by 110
Autism Spectrum Disorder Associated with Germline Heterozygous PTEN Mutations
Frazier, T. W. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037002 · Cited by 37
Metadata
- Authors
- Yehia, L., Ngeow, J., & Eng, C.
- Venue
- Journal of Clinical Investigation
- Published
- 2019-01-07
- Volume
- 129
- Issue
- 2
- Pages
- 452-464
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2907518492
- Cited by
- 179
- References
- 33
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.